Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Pinealon

Our opinion on this compoundSingle-lab provenance

45/100

Khavinson neuropeptide with novel chromatin mechanism claim, bottlenecked by single-source evidence and no RCTs

Here’s the thing about Pinealon: the mechanism story is the most interesting part, and it’s also the part that hasn’t been independently validated. The core claim is that this tripeptide (Glu-Asp-Arg, three amino acids) interacts directly with chromatin and modulates gene expression epigenetically. If thats real, it’s a genuinely novel angle. Short-chain peptides that reach the nucleus and alter transcriptional programs without receptor-mediated signaling would be a fundamentally different pharmacological class from your typical GPCR agonist or growth hormone secretagogue. The proposed downstream effects on MAPK/ERK signaling and serotonin biosynthesis give the compound more mechanistic surface area than most Khavinson bioregulators.

The problem is that every Pinealon paper is essentially one conversation. The Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson is the near-exclusive source. We’ve seen this pattern with Epitalon, and the conclusion is the same: internal consistency within the consortium is reasonable, the preclinical models are appropriate (excitotoxicity, ischemia, oxidative stress, Alzheimer’s dendritic spine work, prenatal neuroprotection), but replication outside the group is essentially absent. Thats a serious evidentiary problem regardless of how clean the mechanism narrative sounds from inside the literature.

What Pinealon has over Epitalon is richer mechanistic territory. The dendritic spine preservation data in AD models are specifically interesting: spine density loss is increasingly recognized as an early structural correlate of cognitive decline, and a compound that modulates it at the gene-expression level would have real probe value if the mechanism holds. The tryptophan hydroxylase upregulation story gives a second, independently testable claim. We like that the hypothesis has multiple experimental handles; it’s not a single-pathway black box.

Clinical evidence is minimal and uncontrolled. Open-label observations in TBI and elderly cognitive decline cohorts exist, but no randomized trials, no multi-site replication. Cortexin, the parent complex fraction with broader post-Soviet clinical use in stroke and TBI, doesnt validate the isolated EDR tripeptide in any direct way. The translational arrow is weak, honestly weaker than the preclinical depth suggests it should be at this stage of development.

Pinealon lands in a frustrating position: genuinely novel mechanism hypothesis, reasonable preclinical breadth across multiple models, entirely constrained by its single-source institutional origin. For a lab already working on neuroprotection or epigenetic peptide biology, it’s a compound worth monitoring as the field matures. As a primary research target right now, the evidence doesnt justify prioritization over better-replicated compounds in the same indication space. The score reflects real mechanistic promise minus the independent verification that hasn’t arrived yet.

Novelty

62

Mechanism promise

58

In-category differentiation

38

Evidence quality

28

Translational signal

30

Research bench value

42

Rationale Novelty comes from the proposed direct chromatin interaction mechanism for a tripeptide, which is genuinely under-explored; evidence quality and translational signal are suppressed by near-total dependence on the Khavinson consortium with no external replication or controlled clinical trials.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic bioregulatory tripeptide (Glu-Asp-Arg) with proposed epigenetic neuromodulatory activity

A synthetic tripeptide bioregulator derived from the pineal gland peptide fraction, investigated as a neuroepigenetic modulator of gene expression with reported neuroprotective, antioxidant, and geroprotective activity in preclinical oxidative stress, ischemia, and neurodegeneration models.

Abstract

Pinealon (EDR peptide; L-glutamyl-L-aspartyl-L-arginine) is a synthetic tripeptide bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson as part of a multigenerational program to identify tissue-specific short-chain peptides capable of modulating gene expression through direct interaction with chromatin. The compound was identified as one of the shortest biologically active sequences within Cortexin, a complex peptide fraction extracted from bovine cerebral cortex tissue that has been used clinically in several post-Soviet jurisdictions for the treatment of traumatic brain injury, ischemic stroke, and cognitive impairment. Pinealon was subsequently synthesized as a standalone tripeptide and advanced through a series of in vitro and in vivo investigations spanning antioxidant activity, neuroprotection, serotonin biosynthesis regulation, dendritic spine preservation in Alzheimer’s disease models, and preliminary open-label clinical observations in elderly patients with cognitive decline and in patients recovering from craniocerebral trauma.

The proposed mechanism of action is unconventional relative to classical receptor-mediated peptide pharmacology. Due to its low molecular weight (418.41 g/mol) and cationic character, Pinealon is reported to penetrate lipid bilayers and nuclear membranes without requiring surface receptor engagement, gaining direct access to chromatin. Molecular modeling and in vitro binding studies from the Khavinson laboratory have identified complementary binding sites in the promoter regions of several genes relevant to neuroprotection and neurodegeneration, including TPH1 (tryptophan hydroxylase 1, the rate-limiting enzyme in serotonin biosynthesis), SOD2 (mitochondrial superoxide dismutase), GPX1 (glutathione peroxidase 1), PPARA and PPARG (peroxisome proliferator-activated receptor alpha and gamma), CASP3 (caspase-3), and APOE (apolipoprotein E). The proposed binding occurs at specific DNA sequences, principally d(CCTGCC)2 and d(CCAGC)2, through sequence-specific steric and electrostatic complementarity with the major groove of double-stranded DNA. The functional consequence is reported to be destabilization of local DNA secondary structure, alteration of histone modification patterns, and increased accessibility of regulatory regions to transcription factors, resulting in upregulation of neuroprotective gene products and downregulation of pro-apoptotic pathways.

Preclinical pharmacology studies, conducted predominantly by the Khavinson group and affiliated Russian laboratories, have reported that Pinealon produces dose-dependent suppression of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells; increases cell viability under oxidative stress conditions; delays ERK1/2 activation in neurons exposed to homocysteine; reduces caspase-3 expression and p53 protein synthesis in brain tissue; increases serotonin synthesis in neuronal cultures of rat cerebral cortex; normalizes superoxide dismutase and glutathione peroxidase activity in the brains of hypoxia-sensitive rats; prevents the loss of mushroom-shaped dendritic spines in hippocampal neurons from 5xFAD transgenic mice (a model of familial Alzheimer’s disease); and protects rat offspring from prenatal hyperhomocysteinemia-induced cognitive deficits. In an open-label clinical observation in 72 patients with traumatic brain injury, addition of Pinealon to standard rehabilitation therapy improved memory function in approximately 59 percent of patients.

No completed, peer-reviewed randomized controlled trial of Pinealon has been published in English-language indexed journals as of the date of this monograph. No Phase 1 formal safety study, no Phase 2 efficacy trial, and no Phase 3 registration study exist in any population. The compound has no approved indication in any jurisdiction recognized by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Virtually all published Pinealon research originates from the Khavinson laboratory and closely affiliated institutions; independent replication by Western academic laboratories is absent. The chromatin-interaction model, while supported by computational molecular modeling and fluorescence microscopy studies from the originating group, has not been independently validated by structural biology methods (X-ray crystallography, cryo-electron microscopy) at the resolution required to confirm the proposed binding geometry. This monograph documents the chemistry, proposed mechanism, preclinical pharmacology, clinical observations, sourcing and handling, and comparative assessment of the compound, and identifies the principal evidence gaps that currently limit its positioning in the research-clinical translation pipeline.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1508Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
ACD856

Our opinion on this compoundNovel, promising

64/100

First-in-class pan-Trk PAM with genuinely novel allosteric kinase mechanism, Phase 1 complete but pre-efficacy

Look, ACD856 is doing something genuinely different from every other neurotrophin-targeting approach we’ve seen reach clinical stages. Most attempts to amplify BDNF or NGF signaling have hit the same wall: direct agonism triggers pain, hyperalgesia, and proliferative effects that kill the program. ACD856 sidesteps that by binding the intracellular kinase domain of TrkA, TrkB, and TrkC and increasing the maximal catalytic velocity rather than mimicking the ligand. It potentiates what’s already there, spatiotemporal specificity intact. That’s not a minor pharmacological distinction, and it’s why the allosteric approach has attracted serious interest where orthosteric Trk programs kept failing.

The scaffold itself is interesting. AlzeCure’s team identified this triazinetrione series through a high-throughput screen of roughly 25,000 compounds and then optimized the lead away from ponazuril (the veterinary antiparasitic ancestor, ACD855) specifically to shorten the elimination half-life to something compatible with once-daily human dosing. That tells you the medicinal chemistry work was deliberate, not lucky. EC50 values sit at 295 nM at TrkB and roughly 330 nM at TrkC, with TrkA slightly weaker at 382 nM. Additional activity at IGF1R and FGFR1 adds an interesting layer, though we’re honest that it complicates clean mechanistic interpretation and warrants careful off-target profiling as the program matures.

What we like about the development status: AlzeCure has completed Phase 0 (IV microdose), Phase 1 SAD, and Phase 1 MAD studies. The compound behaves in humans, pharmacokinetics are characterized, and Phase IIa is in planning. That’s a real clinical footprint for a compound this novel. What we dont like: there is zero human efficacy data yet. None. The translational story is entirely preclinical, cognitive enhancement models in rodents, neurite outgrowth markers, antidepressant-like signals, TBI models. Solid work across multiple indication-relevant assays, but we’ve all seen preclinical Alzheimer’s candidates look exactly this good before failing spectacularly in Phase 2.

The competitive landscape is worth noting. E2511 from Eisai is pursuing Trk-targeting territory and represents a credible competitor worth tracking. By contrast, 7,8-DHF is a partial TrkB agonist with poor CNS penetration and a short half-life that makes it a weak comparator, and LM22A-4 has similar limitations. ACD856 is the cleanest clinical-stage candidate in this specific mechanism class right now, and thats a real structural advantage. But best-in-an-early-stage-field is not the same as validated pharmacology in the target population.

As a bench tool, a selective pan-Trk PAM with sub-micromolar potency across all three receptors would be genuinely useful for dissecting neurotrophin signaling biology. The current toolkit for TrkB work specifically is mediocre; 7,8-DHF has enough liabilities that investigators routinely apologize for using it. If ACD856 becomes more broadly available to academic labs, its probe value improves considerably. Right now availability is the limiting factor given its proprietary status. We score this 64: the mechanism and novelty are real, the evidence base is thin, and the translational signal is preclinical-only. Worth watching closely as Phase IIa readouts come in.

Novelty

78

Mechanism promise

80

In-category differentiation

68

Evidence quality

42

Translational signal

40

Research bench value

65

Rationale ACD856 scores high on novelty and mechanism (first-in-class triazinetrione Trk-PAM, intracellular kinase domain allosterism increasing Vmax rather than substituting for ligand, pan-TrkA/B/C coverage) but evidence quality and translational signal are bounded by Phase 1 PK and safety data only, with zero human efficacy readout; differentiation is real but E2511 from Eisai represents credible competition in the same mechanistic space.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Triazinetrione positive allosteric modulator of tropomyosin receptor kinases (TrkA, TrkB, TrkC) potentiating neurotrophin signaling

A first-in-class triazinetrione pan-Trk positive allosteric modulator developed by AlzeCure Pharma that enhances BDNF and NGF signaling for the treatment of cognitive dysfunction in Alzheimer’s disease, with additional preclinical support for depression, traumatic brain injury, and sleep disorders.

Abstract

ACD856 is a novel, orally bioavailable triazinetrione compound functioning as a positive allosteric modulator (PAM) of the tropomyosin receptor kinases TrkA, TrkB, and TrkC, the principal signal-transducing receptors for the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), respectively [1, 2]. The compound was identified through a high-throughput screening campaign of approximately 25,000 compounds and structurally optimized from the veterinary antiparasitic triazinetrione scaffold shared by toltrazuril and ponazuril (ACD855), with the critical improvement of a substantially shortened elimination half-life suitable for once-daily human dosing [3, 4]. ACD856 potentiates the tropomyosin receptor kinases with EC50 values of 382 nM (TrkA), 295 nM (TrkB), and approximately 330 nM (TrkC), and exhibits additional positive allosteric modulation of the insulin-like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor 1 (FGFR1) [1, 5]. The mechanism of action is distinct from orthosteric Trk agonism: ACD856 binds the intracellular kinase domain of Trk receptors and increases the maximal catalytic velocity (Vmax) of the kinase, thereby amplifying endogenous neurotrophin signaling rather than substituting for it [2, 6]. This allosteric mechanism preserves the spatiotemporal specificity of native neurotrophin activity, a property expected to confer a more favorable safety profile than direct agonist approaches that have historically been limited by pain, hyperalgesia, and off-target proliferative effects.

In preclinical pharmacology, ACD856 has demonstrated reversal of scopolamine-induced and dizocilpine (MK-801)-induced memory impairment in passive avoidance and novel object recognition tasks in mice, restoration of age-related memory deficits in 21-month-old mice to the performance level of young animals following single-dose administration, neuroprotection against amyloid-beta(1-42)-induced synaptotoxicity in primary cortical neurons, enhancement of NGF-stimulated neurite outgrowth in PC12 cells, elevation of BDNF protein levels in the brains of aged mice following repeated dosing, and sustained antidepressant-like effects in the forced swim test persisting up to seven days after the last dose [5, 7, 8]. The compound also enhanced mitochondrial ATP production under energy-deprived conditions, increased phosphorylation of TrkB and ERK1/2 in cortical neurons, elevated hippocampal concentrations of serotonin, noradrenaline, and dopamine by in vivo microdialysis, and increased expression of the presynaptic protein SNAP25, collectively indicating a broad neuroprotective and neuroplasticity-promoting pharmacological profile [5, 7].

ACD856 has completed two Phase 1 clinical studies in healthy volunteers. The single ascending dose (SAD) study (1 to 150 mg oral, n = 56) demonstrated rapid absorption (median tmax 0.33 to 1.0 hours), linear dose-proportional pharmacokinetics, near-complete oral bioavailability (approximately 93 percent relative bioavailability), a terminal elimination half-life of approximately 20 hours supporting once-daily dosing, and an acceptable safety profile with no serious adverse events and no dose-related safety signals [9]. The multiple ascending dose (MAD) study (10, 30, and 90 mg daily for seven days, n = 24) confirmed dose-dependent increases in cerebrospinal fluid concentrations (geometric mean 3.98 to 100 ng/mL), CSF-to-unbound-plasma ratios of 0.37 to 1.20 indicating substantial blood-brain barrier penetration, dose-dependent changes on quantitative electroencephalography (increased theta power and theta/beta ratio) consistent with central target engagement, and continued safety and tolerability with no serious adverse events [10, 11]. AlzeCure Pharma has received a EUR 2.5 million grant from the European Innovation Council to conduct a Phase IIa clinical study of ACD856 in Alzheimer’s disease, with higher doses to be evaluated based on the favorable Phase 1 safety profile [12]. Additional indications under preclinical investigation include depressive disorders, traumatic brain injury, sleep disorders, and postoperative cognitive dysfunction.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1529Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Capromorelin

Our opinion on this compoundEstablished, active research

42/100

Orally active ghrelin receptor agonist with solid Phase II sarcopenia data, vet FDA approval, and a crowded class ceiling

Look, capromorelin is a legitimately credible compound in a field that mostly punishes credibility with crowding. It’s a non-peptide, orally active GHS-R1a agonist from Pfizer’s medicinal chemistry program, pyrazolinone-piperidine scaffold, Ki of 7 nM at the human ghrelin receptor, EC50 of 3 nM in pituicyte GH release assays. Clean pharmacology, rigorous SAR optimization, and an oral bioavailability story that actually held up in clinical PK studies. The development code CP-424,391 shows up in preclinical literature from the early 2000s and the chemistry is well characterized.

The human evidence is better than most people assume. White et al. 2009 was a 395-patient, 12-month multicenter RCT in adults aged 65 to 84 with mild functional limitation. Lean body mass increased 1.6 kg at month 12. Tandem stair climbing power improved versus placebo. GH and IGF-1 remained elevated throughout dosing. Thats a real Phase II result with a functional endpoint and adequate power, not a surrogate-only study with 30 participants. Ellis et al. 2015 added Phase I data across healthy volunteers and spinal cord injured patients showing dose-proportional PK and reasonable tolerability from 20 to 100 mg oral. The Phase II discontinuation before registration trials is the core wound on the record. Pfizer walked away, the reasons are not fully public, and the compound never got its Phase III. That ceiling matters for how seriously investigators should anchor to the clinical promise.

The veterinary approval story is worth understanding on its own terms. Entyce (2016, dogs) and Elura (2020, cats with chronic kidney disease) are full FDA-approved products backed by species-specific pivotal trials. The GHS-R1a mechanism for appetite stimulation and lean mass preservation works well enough in companion animals to clear regulatory review in two separate indications. For researchers studying GH axis pharmacology or orexigenic signaling, that translational validation is not trivial, even if the species difference limits how directly it maps to human research questions.

Here’s the thing: ibutamoren exists. MK-677 shares the non-peptide oral format, has accumulated an enormous research literature, wider investigator familiarity, and dominates the GHS-R1a research conversation by a wide margin. Capromorelin’s half-life in humans runs short and its CYP3A4-heavy metabolism profile isnt obviously better suited to chronic research dosing than ibutamoren. Macimorelin has cleared human FDA approval for AGHD diagnosis. Anamorelin has Japanese approval in cancer cachexia. Capromorelin sits in an awkward middle position: enough evidence to be genuinely credible, not enough to define or lead its class.

We think the Phase II sarcopenia dataset is probably underappreciated and the veterinary approvals make this a more accessible, better-characterized compound than many peptide secretagogues with thinner records. For investigators specifically interested in oral GHS-R1a pharmacology, sarcopenia biomarkers, or orexigenic GH axis biology in models where oral dosing is preferred, capromorelin deserves serious consideration. For general GH secretagogue research, ibutamoren is the more practical starting point, and honestly thats where most programs will land.

Novelty

28

Mechanism promise

38

In-category differentiation

40

Evidence quality

60

Translational signal

52

Research bench value

42

Rationale Capromorelin earns genuine credit for a 395-patient Phase II RCT with statistically significant lean mass and functional outcomes, plus dual FDA veterinary approvals that validate the GHS-R1a mechanism at regulatory standard. Novelty and differentiation are suppressed by the crowded non-peptide GHS-R1a field where ibutamoren dominates the research literature, and Phase III discontinuation caps the translational ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Orally active pyrazolinone-piperidine dipeptide growth hormone secretagogue receptor type 1a (GHS-R1a) agonist

A non-peptide ghrelin receptor agonist developed at Pfizer as a peptidomimetic growth hormone secretagogue for age-related functional decline, subsequently approved in veterinary medicine for appetite stimulation in dogs and weight management in cats with chronic kidney disease.

Abstract

Capromorelin (CP-424,391) is an orally active, non-peptide agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a, the ghrelin receptor) belonging to the pyrazolinone-piperidine dipeptide structural class. The compound was discovered at Pfizer Global Research and Development through systematic structure-activity optimization of peptidomimetic scaffolds and was selected as a clinical development candidate on the basis of high receptor affinity (Ki = 7 nM at human GHS-R1a), potent functional activity (EC50 = 3 nM in rat pituicyte growth hormone release assay), oral bioavailability, and robust in vivo growth hormone secretion in rodent and canine models [1, 2]. Capromorelin mimics the endogenous acylated peptide hormone ghrelin by binding the GHS-R1a receptor on somatotroph cells of the anterior pituitary gland and on hypothalamic neurons, activating Gq/11-coupled phospholipase C signaling, intracellular calcium mobilization, and consequent pulsatile growth hormone release through a pathway mechanistically distinct from and synergistic with the growth hormone releasing hormone (GHRH) receptor pathway. Secondary pharmacological activities include appetite stimulation through hypothalamic orexigenic circuits, transient elevation of circulating cortisol and prolactin, and sustained elevation of insulin-like growth factor 1 (IGF-1) on chronic dosing. In human clinical development, capromorelin advanced through Phase I single ascending dose studies in healthy volunteers and spinal cord injured patients (Ellis et al. 2015), demonstrating safety, tolerability, and dose-proportional pharmacokinetics at oral doses of 20 to 100 mg, and through a Phase II multicenter randomized placebo-controlled trial in 395 older adults aged 65 to 84 years with mild functional limitation (White et al. 2009), in which 12 months of daily oral capromorelin produced statistically significant increases in lean body mass (1.4 kg at 6 months, 1.6 kg at 12 months), growth hormone secretion, IGF-1 concentrations, and tandem stair climbing power compared to placebo [5, 6]. Human clinical development was subsequently discontinued; the compound did not advance to Phase III registration trials for age-related sarcopenia or functional decline. In veterinary medicine, capromorelin oral solution received United States Food and Drug Administration approval in 2016 as Entyce (Aratana Therapeutics, subsequently Elanco Animal Health) for appetite stimulation in dogs at an oral dose of 3 mg/kg once daily, and in October 2020 as Elura for the management of weight loss in cats with chronic kidney disease [7, 8, 9]. These veterinary approvals represent the only registered therapeutic applications of capromorelin as of the most recent monograph revision. The compound is the first and only FDA-approved ghrelin receptor agonist for appetite stimulation in companion animals and demonstrates the translational validity of the GHS-R1a mechanism for orexigenic and anabolic applications. Pharmacokinetics in dogs are characterized by rapid oral absorption (Tmax approximately 0.83 hours), moderate oral bioavailability (44 percent), hepatic metabolism predominantly through CYP3A4 and CYP3A5 mediated N-dealkylation and O-debenzylation, and a short terminal elimination half-life (approximately 1.2 hours in dogs, 2.4 hours in rats) [2, 15, 16]. In humans, single ascending oral doses of 20 to 100 mg produced dose-proportional increases in plasma concentration with broadly similar pharmacokinetic behavior between able-bodied and spinal cord injured participants [5]. The compound is well tolerated at studied doses; the principal adverse events across species are transient hypersalivation, mild emesis, loose stools, and transient increases in serum cortisol and glucose concentrations that normalize within hours of dosing. This monograph reviews the chemistry, synthesis, and structure-activity relationships of capromorelin; the GHS-R1a receptor pharmacology and downstream signaling; the comprehensive pharmacokinetic record across species; the preclinical pharmacology in rodent and canine models; the human clinical evidence base including Phase I and Phase II trials; the veterinary clinical evidence and regulatory approvals; sourcing and quality verification; reconstitution and handling; stack-interaction considerations for research applications; the adverse-event and safety profile; and a comparative assessment of five growth hormone secretagogue candidates (ibutamoren, anamorelin, macimorelin, ipamorelin, tabimorelin) against capromorelin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1541Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Mirabegron

Our opinion on this compoundEstablished, active research

57/100

Approved beta-3 agonist with a genuine second act as a BAT thermogenesis and metabolic research probe

Look, mirabegron has a genuine story here, and it’s not the one Astellas originally told. The OAB approval (FDA 2012, Japan 2011) matters mostly as context. Four Phase 3 trials—SCORPIO, ARIES, CAPRICORN, DRAGON—with 4,500-plus patients established the efficacy case, and the “not-antimuscarinic” angle was genuinely novel at the time. That distinction has faded. Vibegron (Gemtesa) is also a beta-3 agonist now and arguably has a cleaner pharmacokinetic profile and meaningfully less CYP2D6 liability, so mirabegron no longer owns its original category on those terms.

What keeps mirabegron interesting for bench investigators is the brown adipose tissue angle. Beta-3 adrenergic receptors are highly expressed in BAT, and chronic mirabegron treatment in healthy human subjects has been shown to measurably increase BAT metabolic activity, resting energy expenditure, HDL cholesterol, adiponectin, and insulin sensitivity. Thats real human translational data. The mechanism is clean: beta-3 AR activation drives cAMP accumulation, which upregulates uncoupling protein 1 (UCP1) in brown adipocytes, dissipating the proton gradient as heat. It’s not subtle biology, and it’s been demonstrated in people, not just rodents.

What we like: mirabegron is the reference compound for beta-3-mediated BAT activation in human studies. If you’re building a research program around cold-induced thermogenesis, adipose tissue browning, or metabolic reprogramming through sympathomimetic pathways, this is your tool. The clinical pharmacokinetics are thoroughly characterized, CYP2D6 inhibitory activity is quantified and predictable, and you’re not starting from scratch on the safety profile.

What we dont love: the metabolic effect sizes in human studies are real but modest. This isnt going to produce the body composition numbers of a GLP-1 agonist, and the comparison isn’t hypothetical—the field is watching both simultaneously. The tumor microenvironment and oncology angles are preclinical and speculative at this stage; interesting as leads, not yet a serious research argument. And the novelty window for the primary mechanism has largely closed. You’re working with a 14-year-old approved drug whose beta-3 pharmacology is well-mapped.

Honestly, the CYP2D6 inhibition deserves more attention than it typically gets in the research context. Mirabegron at therapeutic concentrations produces clinically meaningful elevations in systemic exposure to CYP2D6 substrates—metoprolol, desipramine, thioridazine—which complicates stack work and requires careful attention in any multi-compound protocol.

The case for mirabegron in a research library is solid but bounded: it’s a well-characterized approved drug with a second life as a beta-3 and BAT biology probe, and that second life has produced real, replicated human data. That’s genuinely useful. It’s not groundbreaking anymore, but it’s not boring either, and for investigators building around adipose thermogenesis or sympathomimetic metabolic biology, it’s the compound you reach for first.

Novelty

35

Mechanism promise

55

In-category differentiation

58

Evidence quality

75

Translational signal

68

Research bench value

62

Rationale Mirabegron’s primary OAB pharmacology is mature and now faces direct competition from vibegron, but replicated human data on beta-3-mediated BAT activation and metabolic effects give it real bench utility as the reference compound for sympathomimetic adipose biology research.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective beta-3 adrenergic receptor agonist with secondary CYP2D6 inhibitory activity

A selective beta-3 adrenoceptor agonist developed by Astellas Pharma as the first non-antimuscarinic oral treatment for overactive bladder, distinguished from the antimuscarinic drug class by its distinct receptor mechanism, favorable dry mouth and cognitive side-effect profile, moderate CYP2D6 inhibitory activity, and emerging research interest in brown adipose tissue thermogenesis, metabolic disease, and oncology.

Abstract

Mirabegron (YM-178) is a selective beta-3 adrenergic receptor (beta-3-AR) agonist approved in over 40 countries for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Developed by Astellas Pharma and first approved in Japan in 2011 and by the United States Food and Drug Administration in June 2012, mirabegron represented a paradigm shift in OAB pharmacotherapy as the first non-antimuscarinic agent approved for the indication, offering clinically meaningful efficacy with a substantially lower incidence of the dry mouth, constipation, and cognitive impairment that limit long-term adherence to antimuscarinic agents such as oxybutynin, tolterodine, solifenacin, darifenacin, and fesoterodine. The compound activates beta-3 adrenergic receptors on detrusor smooth muscle cells, producing cyclic adenosine monophosphate (cAMP)-mediated relaxation of the bladder wall during the storage phase and thereby increasing functional bladder capacity without impairing voiding contractility. At clinically approved doses (25 mg and 50 mg extended-release tablets administered once daily), mirabegron demonstrates high selectivity for the beta-3-AR over beta-1 and beta-2 adrenergic receptor subtypes, although modest beta-1-AR activity at supratherapeutic concentrations has been characterized and contributes to the dose-dependent cardiovascular signal (small increases in heart rate and blood pressure) that is the principal safety consideration in clinical use. The compound is also a moderate inhibitor of cytochrome P450 2D6 (CYP2D6), producing clinically relevant increases in systemic exposure to CYP2D6 substrates including metoprolol, desipramine, and thioridazine, a property that requires attention in polypharmacy contexts. Four pivotal Phase 3 randomized controlled trials (SCORPIO, ARIES, CAPRICORN, and DRAGON) enrolling over 4,500 patients established the efficacy and tolerability of mirabegron at 25 mg and 50 mg doses, demonstrating statistically significant reductions in mean daily micturition frequency and incontinence episodes compared to placebo over 12-week treatment periods, with efficacy sustained through 12-month extension studies. The safety profile in pooled clinical trial data and in extensive postmarketing surveillance confirms a low incidence of dry mouth (comparable to placebo), with the principal treatment-emergent adverse events being hypertension (7 to 11 percent), nasopharyngitis, urinary tract infection, and headache. Cardiovascular safety analyses, including a multinational non-interventional cohort study, have not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators. Beyond the established OAB indication, mirabegron has attracted substantial research interest as a pharmacological activator of brown adipose tissue (BAT) thermogenesis through beta-3-AR-mediated stimulation of uncoupling protein 1 (UCP1) expression. Chronic mirabegron treatment in human subjects has been shown to increase BAT metabolic activity, resting energy expenditure, high-density lipoprotein cholesterol, adiponectin, and insulin sensitivity, positioning the compound as a research tool for metabolic disease and obesity pharmacology. Additional preclinical research has demonstrated antitumor activity through adipose tissue browning and modulation of the tumor microenvironment. This monograph reviews the chemistry, synthesis, and receptor pharmacology of mirabegron; the comprehensive human pharmacokinetic record including CYP2D6 inhibition; the clinical evidence base across OAB and emerging metabolic indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; and a comparative assessment of five OAB pharmacotherapies against mirabegron on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1532Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Paraxanthine

Our opinion on this compoundEstablished, active research

52/100

Caffeine’s major metabolite with a genuinely distinct PDE9-selective mechanism and growing clinical data

Look, paraxanthine sits in an interesting position: everyone’s body makes it already, from caffeine, but that doesn’t mean it’s boring. About 80 percent of caffeine gets converted to 1,7-dimethylxanthine in the liver via CYP1A2, so any time you study caffeine’s effects you’re partly studying paraxanthine’s. The research interest in isolating it as a standalone compound has grown because its mechanism of action diverges meaningfully from the parent methylxanthine at several targets that matter.

The piece we find most interesting is the PDE9 angle. Caffeine is a non-selective phosphodiesterase inhibitor; paraxanthine shows selectivity for PDE9, which preferentially hydrolyzes cGMP. Merck and Boehringer Ingelheim have both run PDE9 inhibitor programs for neurological indications, and paraxanthine overlaps meaningfully with that rationale. That’s not a trivial observation. Combine the PDE9 inhibition with potentiation of nitric oxide signaling and you get a cGMP-elevating mechanism that most stimulant-class compounds don’t offer. The ryanodine receptor activation adds another layer on calcium handling that caffeine also shares, but the composite selectivity profile here is more interesting than “caffeine but weaker.”

The clinical evidence base is modest but real. The enfinity ingredient (Ingenious Ingredients) has been through human trials on cognitive performance, exercise capacity, and energy expenditure, and the tolerability story versus caffeine is the commercial angle they’re working. Less jitter, fewer cardiovascular perturbations at equivalent effective concentrations. The data supports that directionally, though the trial count is nowhere near what youd see from a pharmaceutical compound at this stage. Multiple clinical domains have signal; replication by independent groups is still limited.

For bench investigators, paraxanthine is genuinely useful as a probe. If you want to dissect how much of caffeine’s effect in a model system is mediated by paraxanthine specifically, this is the tool. PDE9 researchers have direct interest; the human PK profile is already established, which matters when moving from cell work to in vivo models. The NO/cGMP angle makes it relevant to vascular and synaptic plasticity research programs. That said, this isn’t the kind of compound that opens a research area you couldn’t access otherwise. It’s more of an important supporting character than a lead molecule.

We place this at established-active. Its a compound that’s earned its own identity separate from caffeine, with a mechanism story more interesting than its precursor. The evidence base is growing but hasn’t caught up to the mechanistic rationale yet. Researchers working on xanthine pharmacology, PDE biology, or adenosine/cGMP crosstalk have clear reasons to care. Everyone else can watch the literature for a couple more years.

Novelty

42

Mechanism promise

62

In-category differentiation

50

Evidence quality

50

Translational signal

55

Research bench value

50

Rationale Paraxanthine earns its separation from caffeine on mechanistic grounds: selective PDE9 inhibition and NO signaling potentiation are meaningfully distinct from its parent compound. Clinical evidence in cognitive, metabolic, and exercise domains exists but remains modest in replication breadth, placing this squarely in established-active territory rather than the frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dimethylxanthine adenosine receptor antagonist and selective cGMP-preferring phosphodiesterase (PDE9) inhibitor

The principal dimethylxanthine metabolite of caffeine in humans, distinguished from the parent compound and from other methylxanthines by selective inhibition of cGMP-preferring phosphodiesterase 9, potentiation of nitric oxide signaling, ryanodine receptor channel activation, and a favorable safety profile relative to caffeine.

Abstract

Paraxanthine (1,7-dimethylxanthine) is the primary metabolite of caffeine in humans, accounting for approximately 80 percent of caffeine biotransformation through hepatic cytochrome P450 1A2 (CYP1A2) catalyzed N3-demethylation. Although structurally an isomer of the naturally occurring dimethylxanthines theophylline (1,3-dimethylxanthine) and theobromine (3,7-dimethylxanthine), paraxanthine is not produced by plants and is encountered in human plasma exclusively as a product of caffeine metabolism. The compound has received escalating research attention since the mid-2000s as a pharmacologically distinct entity rather than a mere intermediate metabolite, with a mechanism of action profile that diverges meaningfully from caffeine at several molecular targets.

The principal pharmacological activities of paraxanthine are competitive antagonism at adenosine A1 and A2A receptors (with binding affinities comparable to or modestly greater than caffeine), selective inhibition of the cGMP-preferring phosphodiesterase PDE9 (an activity not shared by caffeine, theophylline, or theobromine), potentiation of nitric oxide neurotransmission (a unique property among the naturally occurring methylxanthines), and activation of ryanodine receptor calcium release channels (the mechanism underlying its neuroprotective activity in dopaminergic cell models). The composite pharmacology produces psychostimulant, procognitive, neuroprotective, lipolytic, and ergogenic effects that are quantitatively and qualitatively distinguishable from those of caffeine in both preclinical and clinical studies.

Pharmacokinetically, paraxanthine is generated in the liver from caffeine with a formation half-life determined by CYP1A2 activity and reaches plasma concentrations that exceed those of the parent compound approximately 8 to 10 hours after caffeine ingestion. When administered exogenously as pure paraxanthine, the compound exhibits an elimination half-life of approximately 3.1 hours (shorter than caffeine at 4.1 hours, theophylline at 6.2 hours, and theobromine at 7.2 hours), rapid oral absorption, and dose-proportional pharmacokinetics across the studied range of 100 to 400 mg. The shorter half-life contributes to a cleaner offset of stimulant effects and reduced sleep disruption relative to caffeine at equimolar doses.

Clinical evidence from double-blind, placebo-controlled crossover trials demonstrates that acute oral paraxanthine at 100 to 200 mg improves sustained attention, working memory, executive function, reaction time, and psychomotor vigilance in healthy adults, with effects comparable to or exceeding those of caffeine on several cognitive endpoints and with fewer reported adverse events. A 2024 study demonstrated superior cognitive maintenance after a 10-kilometer run compared to caffeine, with caffeine-treated subjects committing 31 percent more errors while paraxanthine-treated subjects improved correct responses by approximately 6.8 percent. Preclinical studies in rodents have demonstrated that paraxanthine supplementation increases muscle mass by 14 to 41 percent, forelimb grip strength by 17 percent, and treadmill endurance by 39 percent relative to control. Paraxanthine has also been shown to enhance brain-derived neurotrophic factor (BDNF) levels, elevate hippocampal acetylcholine and dopamine, and provide neuroprotection against MPTP-induced dopaminergic cell death through ryanodine receptor channel activation.

The safety profile of paraxanthine is favorable relative to caffeine. In 90-day repeat-dose oral toxicity studies in rats, the no-observed-adverse-effect level (NOAEL) for paraxanthine was established at 185 mg/kg body weight compared to 150 mg/kg for caffeine; mortality was observed in two rats receiving caffeine at 185 mg/kg but in none receiving paraxanthine at the same dose. The acute oral LD50 in rats is 829.20 mg/kg. In vitro genotoxicity and mutagenicity studies are negative. In human clinical studies, acute and 7-day daily ingestion of paraxanthine at doses up to 300 mg has not been associated with clinically significant adverse events, changes in blood pressure, or anxiogenic effects at the magnitude observed with equivalent caffeine doses. The ingredient has achieved self-affirmed Generally Recognized as Safe (GRAS) status for use in food and beverages in the United States at levels up to 300 mg per serving. This monograph reviews the chemistry, synthesis, and structural relationships of paraxanthine; the multi-target mechanism of action; the comprehensive pharmacokinetic record; preclinical pharmacology across cognitive, neuroprotective, ergogenic, and metabolic endpoints; the clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety; and a comparative assessment of five methylxanthine and stimulant alternatives against paraxanthine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1523Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Thymalin

Plain-language summaryIntrigue 58 / 100

Thymalin is a Russian-developed bovine thymus peptide preparation used as an immunomodulator for elderly patients and immune disorders. Combined with epitalon in Khavinson’s longevity research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

40/100

A Soviet-era thymic polypeptide complex with interesting chromatin-level mechanism claims, but evidence almost entirely from one Russian consortium

Look, Thymalin occupies a genuinely interesting but frustrating position in the immunomodulatory peptide space. It’s a standardized extract from calf thymus developed in Leningrad in the 1970s, registered as a pharmaceutical in the Soviet Union in 1982, and it’s been in clinical use in Russia for over four decades. That’s not nothing. But here’s the problem: almost everything we know about it comes from the same research group at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson and colleagues. That pattern should immediately activate your replication skepticism.

The mechanism story is actually the most interesting part. The Khavinson group’s proposal is that short peptides within the extract bind selectively to double-stranded DNA sequences and histone proteins, modulating chromatin conformation and downstream gene expression for immune proteins. That’s an epigenetic framing for a thymic extract, and it’s more sophisticated than “it’s a cytokine stimulator.” The identification of active constituent peptides (Glu-Trp, Lys-Glu, and Glu-Asp-Pro) via HPLC and the subsequent independent development of those constituents as separate compounds (Thymogen, Vilon, Crystagen) does give the mechanistic story some structural support. The pieces fit together in a way that isnt obviously fabricated.

The clinical numbers look impressive on paper. The 6-to-8-year mortality study in 266 elderly subjects showing 2-fold lower mortality. The COVID-19 randomized single-blind trial in 80 patients showing halved in-hospital mortality and a 6.5-fold reduction in IL-6. If these results hold up, they’re paradigm-relevant. But they havent been replicated outside the originating consortium, and “single-blind” in an injection study is considerably weaker than double-blind. The effect sizes are large enough to warrant serious independent replication, but that replication hasn’t happened. It’s the same problem as Epitalon with a slightly more credible clinical package attached.

What makes Thymalin distinct from its thymic peptide competitors is the multicomponent nature of the extract. Thymosin alpha-1 is a single defined sequence with international trial data; Thymalin is a fraction soup that happens to contain interesting short peptides. For some research questions that’s a feature (it represents a more physiological immune stimulus than a single-sequence synthetic). For others it’s a liability: you can’t cleanly attribute effects to any single component. If you want a cleaner tool for studying thymic peptide biology at the chromatin level, Thymogen or Vilon are probably better probes for specific mechanisms.

Honestly, this is a compound worth watching but not a priority bench investment right now. The COVID-19 signal, if real, deserves independent replication. The chromatin-level mechanism story deserves clean in vitro work outside St. Petersburg. Until that happens, Thymalin sits in the same frustrating bucket as Cerebrolysin: real clinical history, interesting mechanistic framing, evidence base that’s deeply tied to a single institution and hard to evaluate on its merits.

Novelty

32

Mechanism promise

50

In-category differentiation

40

Evidence quality

35

Translational signal

42

Research bench value

38

Rationale Thymalin has a genuine 40-year pharmaceutical registration record in Russia and the peptide-DNA/histone binding mechanism is more sophisticated than typical immunomodulator framing, but the Khavinson/St. Petersburg Institute group dominates essentially all serious literature; the striking COVID-19 mortality signal and geroprotective outcome data are unreplicated outside the originating consortium, placing it squarely in the single-lab-only tier despite a higher clinical pedigree than Epitalon.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Thymic polypeptide bioregulator complex with immunomodulatory and geroprotective activity

A heterogeneous polypeptide complex isolated from calf thymus, developed at the Military Medical Academy in Leningrad as a thymic bioregulator for immune restoration, distinguished from other thymic peptide preparations by its multicomponent composition containing the immunomodulatory dipeptides L-glutamyl-L-tryptophan and L-lysyl-L-glutamic acid and the tripeptide L-glutamyl-L-aspartyl-L-proline.

Abstract

Thymalin is a standardized polypeptide complex isolated from the thymus gland of calves by acid hydrolysis and ultrafiltration, containing peptide fractions in the 1,000 to 10,000 dalton molecular weight range. Developed at the Military Medical Academy in Leningrad (now Saint Petersburg) by Vladimir Khavinson and Vyacheslav Morozov in the 1970s, the preparation was registered as an immunomodulatory pharmaceutical in the Soviet Union in 1982 and has remained in clinical use in the Russian Federation for more than four decades. Unlike the structurally defined thymic peptides thymosin alpha-1 (a 28-amino-acid single-sequence peptide), thymulin (a zinc-dependent nonapeptide), and thymopentin (a synthetic pentapeptide fragment of thymopoietin), Thymalin is a multicomponent extract whose principal bioactive constituents have been identified by reversed-phase high-performance liquid chromatography as the dipeptide L-glutamyl-L-tryptophan (Glu-Trp, subsequently developed independently as Thymogen), the dipeptide L-lysyl-L-glutamic acid (Lys-Glu, developed as Vilon), and the tripeptide L-glutamyl-L-aspartyl-L-proline (Glu-Asp-Pro, developed as Crystagen). The molecular mechanism of the immunoprotective activity is attributed to the capacity of these short peptides to bind selectively to double-stranded DNA sequences and to histone proteins, thereby modulating chromatin conformation, gene expression, and the synthesis of immune system proteins including interleukins, interferons, heat-shock proteins, and components of the fibrinolytic system. In experimental systems, Thymalin stimulates the differentiation and functional activity of T-lymphocyte subpopulations (CD4+ and CD8+), normalizes the ratio of T-helper to T-suppressor cells, enhances natural killer cell activity and phagocytosis, and modulates the balance between pro-inflammatory and anti-inflammatory cytokines. The geroprotective properties of Thymalin are supported by a prospective clinical observation of 266 elderly subjects over 6 to 8 years conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences, in which Thymalin-treated subjects exhibited 2.0- to 2.1-fold lower mortality compared to controls receiving standard geriatric care, with further reductions (4.1-fold lower mortality) observed in a subgroup receiving annual combined Thymalin and Epithalamin treatment for 6 years. More recently, a prospective randomized single-blind controlled trial of Thymalin (10 mg intramuscular daily for 10 days) in 80 elderly patients with severe COVID-19 reported a 92 percent increase in blood lymphocytes, 6.5-fold reduction in interleukin-6, halved in-hospital mortality (19.4 percent versus 40.9 percent in controls), and more rapid clinical improvement (80.5 percent versus 59 percent). In vitro studies have demonstrated that Thymalin reduces expression of the stem cell markers CD44 and CD117 by 2- to 3-fold while increasing expression of CD28 (a marker of mature T lymphocytes) by 6.8-fold, consistent with stimulation of hematopoietic stem cell differentiation into functional T cells. The compound is administered by intramuscular or subcutaneous injection in short cyclical courses of 5 to 10 days at doses of 5 to 10 mg daily, with clinical effect reported to persist for weeks to months following each treatment course. The safety record across more than 40 years of clinical use indicates minimal adverse events, principally limited to injection-site reactions. This monograph reviews the composition, extraction, and characterization of Thymalin; the molecular pharmacology of its constituent peptides at the level of DNA binding, histone interaction, and gene expression regulation; the pharmacokinetic properties; the preclinical evidence base across immune restoration, geroprotection, and oncology models; the clinical evidence in elderly immune decline, respiratory infections, perioperative immune suppression, and COVID-19; sourcing and quality verification considerations; reconstitution and handling protocols; stack interactions with other immunomodulatory agents; the adverse-event and safety profile; and a comparative assessment of five alternative thymic and immunomodulatory peptide preparations against Thymalin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1504Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Emodin

Our opinion on this compoundEstablished workhorse

32/100

Active preclinical subject with multi-target MoA, but clinical translation is nearly absent and safety baggage is real

Look, emodin has been kicking around in pharmacology longer than most investigators have been alive. The anthraquinone backbone was first isolated from Himalayan rhubarb in the 19th century, and Rheum palmatum preparations have two millennia of traditional use behind them. Thats not novelty; thats a compound that modern pharmacology keeps reexamining hoping to find something it missed. Sometimes that pays off. Here, the verdict is mixed.

The mechanism story is legitimately interesting on paper. Emodin isn’t a single-target molecule: it inhibits NF-kB transcriptional activity, activates AMPK, suppresses the PI3K/Akt/mTOR axis, directly inhibits casein kinase II and p56lck, and modulates STAT3 and HIF-1alpha. That composite profile spans anti-inflammatory, antitumor, antifibrotic, antiviral, and metabolic territories. We’d be more impressed if this breadth translated into selectivity for any one research program, but it doesn’t. When a compound hits NF-kB, AMPK, mTOR, and multiple kinases simultaneously, you’re not running clean experiments. The promiscuity that makes the pharmacology look rich is exactly what makes emodin a poor probe.

The preclinical literature is genuinely multi-lab and spans a wide range of models: hepatocellular carcinoma, pancreatic cancer, colitis, NAFLD, renal fibrosis, and viral targets including SARS-CoV-2 protease inhibition. There’s no shortage of data. What there is a shortage of is any clean, well-designed human trial on emodin itself. The clinical section of this monograph covers traditional herbal formulations and diacerein, a pro-drug of the structurally related rhein, which actually achieved regulatory approval for osteoarthritis in some jurisdictions. Emodin specifically has not cleared that bar, and the barriers are not trivial: dose-dependent hepatotoxicity, nephrotoxicity at higher exposures, genotoxicity signals in multiple assays, and reproductive toxicity findings that complicate any serious IND-level conversation. Bioavailability is also a chronic problem, with extensive first-pass metabolism and poor systemic exposure from oral dosing.

What we think emodin is useful for: anthraquinone class characterization, comparative structure-activity work within the Polygonaceae-derived compound space, and as a reference compound in NF-kB or CKII inhibition assays where its activity is well-documented enough to serve as a positive control. What it isn’t useful for: anchoring a serious translational research program. The literature is wide and shallow, the safety profile limits what you can do with it in vivo, and any effect you observe is mechanistically ambiguous by design.

Honestly, if your program is metabolic or oncologic, you have better-characterized tools. If you’re specifically studying anthraquinone pharmacology or TCM-adjacent natural product chemistry, emodin is the reference compound by volume of literature. That’s a real but narrow role, and the score reflects it.

Novelty

22

Mechanism promise

50

In-category differentiation

32

Evidence quality

33

Translational signal

18

Research bench value

40

Rationale Emodin is a decades-old natural product with genuine mechanistic breadth (NF-kB, AMPK, CKII, PI3K/Akt/mTOR) and a large multi-lab preclinical footprint, but the clinical evidence base for isolated emodin is essentially nil, the translational arrow is weak due to hepatotoxicity and genotoxicity signals, and the compound is too promiscuous to serve as a clean probe. Scores land it in the lower established-mature band with no applicable hard cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Natural anthraquinone derivative with multi-target anti-inflammatory, antitumor, and metabolic regulatory activity

A 1,3,8-trihydroxy-6-methylanthraquinone isolated from Rheum palmatum and related Polygonaceae species, characterized by pleiotropic pharmacology spanning NF-kappaB inhibition, AMPK activation, kinase modulation, and broad-spectrum antimicrobial activity, with longstanding traditional use and emerging preclinical validation across oncology, metabolic disease, and inflammatory indications.

Abstract

Emodin (1,3,8-trihydroxy-6-methylanthraquinone; CAS 518-82-1) is a naturally occurring anthraquinone derivative present in the roots and rhizomes of multiple medicinal plant species, most notably Rheum palmatum L. (Chinese rhubarb), Polygonum cuspidatum (Japanese knotweed), Polygonum multiflorum (He Shou Wu), Cassia obtusifolia, and Aloe vera. The compound has been a constituent of traditional Chinese medicine preparations for over two millennia, with rhubarb first recorded in the Shen Nong Ben Cao Jing, the earliest systematic pharmacopoeia of traditional Chinese medicine. Modern pharmacological investigation has revealed emodin to be a pleiotropic bioactive molecule operating through multiple convergent signaling pathways, including inhibition of nuclear factor kappa B (NF-kappaB) transcriptional activity, activation of AMP-activated protein kinase (AMPK), suppression of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) axis, modulation of peroxisome proliferator-activated receptor gamma (PPARgamma), and direct inhibition of casein kinase II (CKII) and the protein tyrosine kinase p56lck. These molecular activities produce a composite pharmacological profile encompassing anti-inflammatory, antitumor, antiviral, antibacterial, antifibrotic, hepatoprotective (at low doses), antidiabetic, and immunomodulatory effects demonstrated across extensive in vitro and in vivo preclinical models.

The antitumor activity of emodin has been characterized in cell culture and rodent xenograft models against pancreatic, hepatocellular, breast, lung, colorectal, and prostate carcinomas, with mechanisms including induction of caspase-dependent apoptosis, cell cycle arrest at the G2/M checkpoint, suppression of matrix metalloproteinase-mediated invasion, inhibition of angiogenesis through vascular endothelial growth factor downregulation, and reversal of gemcitabine resistance through IKKbeta/NF-kappaB pathway suppression. The anti-inflammatory profile operates primarily through suppression of NF-kappaB-driven proinflammatory cytokine release (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) and through NLRP3 inflammasome inhibition. Antiviral activity has been demonstrated against more than ten viral species in vitro and in vivo, including herpes simplex virus types 1 and 2, influenza A virus, coxsackievirus B3, hepatitis B virus, and SARS-CoV. Antibacterial activity is notable against Gram-positive organisms, with minimum inhibitory concentrations against Staphylococcus aureus and Mycobacterium tuberculosis in the low-micromolar range.

The principal pharmacokinetic limitation of emodin is extremely poor oral bioavailability, approximately 3 percent in rodent models, attributable to rapid and extensive phase II glucuronidation by UDP-glucuronosyltransferases (UGT1A1, UGT1A9, UGT2B7) in both intestinal epithelium and hepatocytes, with additional contributions from CYP1A2 and CYP2E1 oxidative metabolism. Approximately 56 percent of an oral dose is unabsorbed and excreted in feces as parent compound. This pharmacokinetic barrier has substantially limited clinical translation despite extensive preclinical efficacy data. Strategies to overcome poor bioavailability include co-administration with the glucuronidation inhibitor piperine (which produces a 221 percent increase in area under the curve in rodent models), nanoparticle encapsulation, liposomal formulation, polymeric lipid hybrid nanoparticles, and solid lipid nanoparticle delivery systems.

Toxicological evaluation has identified dose-dependent hepatotoxicity, nephrotoxicity, and reproductive toxicity at sustained high doses. Hepatotoxicity is mediated in part through inhibition of hepatocyte nuclear factor 4 alpha expression and consequent downregulation of UGT2B7, creating a paradoxical positive feedback loop in which high-dose emodin impairs its own principal detoxification pathway. Nephrotoxicity occurs through induction of apoptosis in proximal tubular epithelial cells via PPARgamma-related mitochondrial pathways. Reproductive toxicity includes disruption of testicular gene expression and inhibition of human sperm calcium signaling and tyrosine phosphorylation in vitro. The compound is not approved as a pharmaceutical agent by any major regulatory authority. It is classified as a dietary supplement ingredient and research compound. This monograph reviews the chemistry, natural sourcing, and structural characterization of emodin; the multi-pathway molecular pharmacology; the comprehensive pharmacokinetic record including glucuronidation-dominated metabolism; the preclinical evidence base across oncology, inflammatory, metabolic, infectious disease, and fibrotic indications; the limited clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and toxicity profile; and a structured comparative assessment of five anthraquinone derivatives (chrysophanol, rhein, aloe-emodin, diacerein, physcion) against emodin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1540Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
HGH

Our opinion on this compoundResearch workhorse

51/100

Gold-standard GH axis reference compound; novelty is spent but evidence depth is unmatched

Here’s the thing about somatropin: it IS the GH axis. Every secretagogue paper, every GHRP, every ipamorelin or CJC-1295 study is calibrated against it. That reference-standard position gives it real bench utility, but it also means the compound itself is about as exploratory as a positive control. When you’re running rhGH, you’re not discovering anything new about growth hormone biology. You’re confirming your assay works.

The mechanism is textbook. GHR dimerization, JAK2 activation, STAT5 phosphorylation, liver-derived IGF-1 in a ternary IGFBP-3/ALS complex — this is chapter two of any endocrinology monograph. We’re not in territory where we think we understand it but there’s something interesting we dont fully know. We understand it. The interesting mechanistic questions in GH biology today involve pulse amplitude encoding, receptor sensitization states, and GH resistance phenotypes. Those questions are mostly being answered with secretagogues and receptor tools, not direct rhGH infusion.

Evidence quality is where somatropin genuinely stands apart from most compounds in the Kodiac library. Genotropin, Norditropin, Humatrope, Sogroya, Skytrofa — decades of phase 3 data, multiple approved indications, pharmacovigilance databases that dwarf the entire preclinical literature for most peptides we stock. The pediatric GHD evidence base alone is a tier above nearly anything else here. If you want to understand what adequate GH replacement does to bone mineral density, lean mass, or lipid partitioning, you have solid ground under your feet.

Translational signal in approved indications is real and strong: HIV-associated wasting, short bowel syndrome, adult GHD replacement, Turner syndrome. Where it gets more contested is in off-label body composition research in eugonadal adults, where effect sizes are modest and the neoplastic risk profile creates legitimate constraints on research design. The Rudman 1990 NEJM paper launched a thousand investigations, and the aggregate conclusion is: effects are real but substantially context-dependent, reversible, and nowhere near the magnitude early enthusiasm suggested.

What we actually find useful about rhGH in a 2025 research context is the comparator role. If you’re characterizing a novel secretagogue, you probably need a rhGH arm. If you’re investigating IGF-1 kinetics under different stimulation protocols, rhGH is your direct intervention. That bench role earns real points here. But as a primary research target — something an investigator would build a program around — the compound’s time as a frontier object is long past. The score reflects exactly that: exceptional evidence and translational history, low novelty, and a mechanism so well-mapped that the interesting work happens downstream of it.

Novelty

22

Mechanism promise

28

In-category differentiation

55

Evidence quality

80

Translational signal

72

Research bench value

68

Rationale Somatropin scores high on evidence and translational signal because it’s a fully approved drug with decades of phase 3 data, but novelty and mechanism promise are minimal — the GH/IGF-1 axis is textbook biology. Research value is largely as a comparator benchmark; the live investigative action has moved to secretagogues, receptor modulators, and downstream axis components.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Recombinant 191-amino-acid somatotropin protein hormone acting through the GH receptor/JAK2-STAT5/IGF-1 axis

A recombinant human growth hormone (somatropin) identical to endogenous pituitary-derived 22-kDa somatotropin, administered by subcutaneous injection for replacement therapy in pediatric and adult growth hormone deficiency, and investigated for body composition optimization, bone density, anti-aging physiology, and recovery from catabolic states.

Abstract

Human growth hormone (HGH), designated pharmacologically as somatropin in its recombinant form, is a 191-amino-acid, single-chain, non-glycosylated polypeptide of approximately 22,124 daltons produced by recombinant DNA technology in Escherichia coli or mammalian cell expression systems. The compound is structurally and functionally identical to the predominant 22-kDa isoform of endogenous somatotropin secreted by somatotropic cells of the anterior pituitary gland. Recombinant somatropin binds to the extracellular domain of the transmembrane growth hormone receptor (GHR), inducing receptor dimerization and activation of the Janus kinase 2 (JAK2) signaling cascade, with downstream phosphorylation of signal transducers and activators of transcription (STAT1, STAT3, STAT5), mitogen-activated protein kinase (MAPK/ERK), and phosphatidylinositol 3-kinase (PI3K/Akt) pathways. The principal systemic mediator of somatropin action is insulin-like growth factor 1 (IGF-1), a 70-amino-acid peptide synthesized predominantly in hepatocytes under direct GH receptor stimulation and released into the circulation bound to IGF-binding proteins (IGFBPs), principally IGFBP-3 in a ternary complex with the acid-labile subunit (ALS). The GH/IGF-1 axis governs linear bone growth in children, anabolic protein metabolism, lipolysis, glucose counter-regulation, and tissue repair across the lifespan.

The clinical development of exogenous growth hormone spans seven decades. Maurice Raben administered cadaveric pituitary-derived human growth hormone to a growth-hormone-deficient child in 1958, establishing proof of concept for replacement therapy. Cadaveric extraction remained the sole source until 1985, when reports of iatrogenic Creutzfeldt-Jakob disease (CJD) in recipients of pituitary-derived hormone prompted immediate suspension of cadaveric programs worldwide. Genentech received United States Food and Drug Administration (FDA) approval in October 1985 for somatrem (methionyl-HGH, Protropin), the first recombinant growth hormone product, followed by approval of somatropin (Humatrope, Eli Lilly) in 1987. As of 2026, multiple recombinant somatropin formulations are FDA-approved for pediatric growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, small for gestational age (SGA) with failure of catch-up growth, idiopathic short stature (ISS), SHOX deficiency, chronic renal insufficiency, and Noonan syndrome in children, and for adult GHD and HIV-associated wasting. Long-acting formulations (somapacitan, somatrogon, lonapegsomatropin) have been approved since 2020 to reduce injection burden from daily to weekly administration.

Pharmacokinetics of subcutaneous somatropin are characterized by slow absorption from the injection depot (time to peak plasma concentration 3 to 5 hours), absolute bioavailability of approximately 70 to 80 percent, volume of distribution of approximately 0.07 L/kg (intravenous) to 1.3 L/kg (subcutaneous, apparent), and elimination half-life of approximately 3 to 4 hours following subcutaneous administration compared to 0.36 hours following intravenous injection. Clearance occurs principally through hepatic and renal proteolytic catabolism. The pharmacodynamic effect, mediated through sustained elevation of circulating IGF-1, persists substantially longer than the plasma half-life of the parent molecule, with IGF-1 levels remaining elevated for 18 to 28 hours after a single subcutaneous dose.

Clinical evidence for somatropin in pediatric GHD is extensive and unequivocal: meta-analyses of controlled trials demonstrate mean adult height gains of 4 to 8 centimeters above predicted untreated height over treatment courses of 3 to 10 years. In adults with documented GHD, randomized placebo-controlled trials demonstrate reduction of trunk fat mass (8 to 16 percent), increase in lean body mass (2 to 5 kg), improvement in bone mineral density at lumbar spine and femoral neck, improvement in lipid profiles (reduction in LDL cholesterol, increase in HDL cholesterol), and improvement in quality-of-life measures. The principal adverse events of somatropin therapy are dose-dependent and related to fluid retention: peripheral edema, arthralgia, myalgia, carpal tunnel syndrome, and paresthesia, occurring more frequently in adults than in children and generally resolving with dose reduction. Insulin resistance with impaired glucose tolerance is a recognized metabolic consequence of supraphysiologic GH exposure and requires monitoring. Long-term surveillance data from registries including KIGS, HypoCCS, NordiNet IOS, and the French SAGhE cohort have not demonstrated a consistent increase in de novo malignancy risk in patients treated for GHD without pre-existing risk factors, although the SAGhE study reported a modestly elevated standardized mortality ratio in patients treated with higher doses during childhood.

This monograph reviews the molecular biology, structural chemistry, and signal transduction pharmacology of recombinant somatropin; the comprehensive pharmacokinetic record; the clinical evidence base across pediatric and adult GHD, body composition, bone metabolism, and investigational applications; sourcing, reconstitution, and handling considerations for research use; stack interactions with secretagogues, IGF-1, insulin, and thyroid hormones; the adverse event and long-term safety profile; and a structured comparative assessment of five alternative approaches to GH axis modulation (sermorelin, tesamorelin, CJC-1295, ipamorelin, and ibutamoren/MK-677) against recombinant somatropin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1548Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Topilitumide

Our opinion on this compoundNiche research probe

44/100

Serum-labile topical antiandrogen with elegant PK design, thin Phase 3 evidence, and narrow bench utility

Look, the design story here is genuinely clever. Biophysica took the flutamide scaffold, grafted perfluoroacyl moieties onto it, and produced a molecule that behaves like a potent androgen receptor antagonist in dermal tissue and then falls apart in serum before it can drive systemic effects. Half-life in human serum sits around 6 hours at 37°C; parent compound is undetectable after 48 hours of chronic topical use. Thats not accident, that’s deliberate medicinal chemistry solving a real problem: how do you block AR in the scalp without the sexual adverse effects and hepatotoxicity that effectively ended systemic antiandrogens as AGA treatments in most clinical contexts?

The mechanism has two layers worth noting. Topilutamide isn’t only an AR antagonist; it also drives AR protein downregulation in dermal target tissue, which produces more durable local effect than simple competitive antagonism alone would predict. Against the main comparators in topical AGA research, its pharmacokinetic profile is genuinely unique. Clascoterone (Winlevi) is FDA-approved and steroidal, with documented systemic absorption. Topical bicalutamide works but isn’t serum-labile. The 5-alpha reductase inhibitors target a different step in the androgen axis and carry their own systemic liability. In the specific question of local scalp AR blockade without systemic consequences, topilutamide stands alone as a validated approach.

Here’s the thing, though: the evidence base is thin. The monograph explicitly flags the absence of Phase 2 and Phase 3 data. What exists is a pivotal trial in male AGA and an open-label study in women, both supporting efficacy at the 2% concentration marketed as Eucapil in Czech Republic and Slovakia. That’s a limited regulatory footprint by modern standards, and outside Central Europe the compound has essentially no clinical presence or independent replication from outside the original development group.

For a bench investigator, that gap is interesting rather than disqualifying. The serum-labile local AR probe gives you something oral antiandrogens can’t: the ability to study androgen receptor biology in skin without confounding the whole endocrine axis. That’s a genuinely clean experimental tool for AGA pathophysiology research or topical drug delivery programs with pharmacokinetic engineering ambitions. We think that specific utility is real, even if it’s narrow.

What we don’t think is that this compound is broadly compelling right now. Clinical development stalled early, Eucapil hasn’t generated the independent replication data you’d want to justify serious research investment, and the novelty sits at the medicinal chemistry level rather than the biology level. Strong design rationale, weak evidence, modest novelty: that combination puts topilutamide squarely in “worth knowing about” rather than “worth studying now.”

Novelty

40

Mechanism promise

52

In-category differentiation

52

Evidence quality

30

Translational signal

38

Research bench value

48

Rationale Topilutamide earns its scores on the strength of a genuinely clever medicinal chemistry concept (serum-labile AR antagonist with AR protein downregulation in dermal tissue) and a unique position among topical antiandrogens, but the monograph’s explicit acknowledgment of absent Phase 2/3 data and the compound’s confinement to Central European markets cap both evidence quality and translational signal; its primary research value is as a clean probe for dissecting local scalp AR biology without systemic confounds, which is real but narrow.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Topical nonsteroidal antiandrogen of the perfluoroacylamido-arylpropanamide class with rapid serum hydrolysis and local androgen receptor suppression

A rationally designed, serum-labile topical antiandrogen engineered from the flutamide scaffold for androgen receptor suppression in dermal tissue without systemic absorption, developed by Biophysica Inc. and marketed as Eucapil for androgenetic alopecia in Central European jurisdictions.

Abstract

Topilutamide (International Nonproprietary Name; also known as fluridil and by the development code BP-766) is a nonsteroidal antiandrogen of the perfluoroacylamido-arylpropanamide structural class, rationally designed for topical application in the treatment of androgenetic alopecia. The compound represents a deliberate medicinal chemistry solution to the principal limitation of systemic nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide: hepatotoxicity and sexual adverse effects arising from systemic androgen receptor blockade. The design strategy incorporated perfluoroalkyl moieties into the flutamide analog BP-34 to produce a molecule that retains high-affinity androgen receptor antagonism and androgen receptor protein downregulation in dermal tissue while undergoing rapid hydrolytic decomposition upon contact with human serum (half-life approximately 6 hours at 37 degrees Celsius; undetectable after 48 hours), yielding the inactive fragments BP-34 and trifluoroacetic acid. Neither parent compound nor metabolites have been detected in human serum following chronic topical application at the marketed 2 percent concentration, establishing a pharmacokinetic profile that functionally eliminates systemic antiandrogenic exposure.

In vitro pharmacology in LNCaP human prostate cancer cells demonstrates concentration-dependent suppression of androgen receptor protein expression: approximately 40 percent reduction at 3 micromolar and up to 95 percent reduction at 10 micromolar following 48-hour incubation [1, 2]. Comparative binding studies suggest that topilutamide binds the androgen receptor with approximately 9- to 15-fold greater affinity than bicalutamide and hydroxyflutamide, though these findings require further validation with rigorous competitive binding assays [2]. The mechanism appears to involve both direct receptor antagonism and receptor protein downregulation, distinguishing topilutamide from pure competitive antagonists that stabilize the receptor in an inactive conformation.

The clinical evidence base is limited to two published trials comprising 53 total participants. The pivotal randomized, double-blind, placebo-controlled trial in 43 men with androgenetic alopecia demonstrated significant promotion of anagen-phase hair growth: anagen percentage increased from 75.7 percent to 85.1 percent at 3 months and 87 percent at 9 months with daily topical application of 2 percent fluridil in isopropanol vehicle [3]. Sexual function, libido, hematology, and blood chemistry values remained within normal limits throughout the study period, and no systemic absorption of the parent compound or its metabolites was detectable. A second open-label study in 11 women with female pattern hair loss demonstrated significant increases in hair shaft diameter at 6 and 9 months but did not achieve statistical significance on anagen-telogen ratio endpoints [4]. The compound was introduced for cosmetic use in 2003 and is marketed exclusively in the Czech Republic and Slovakia by Interpharma Praha (a subsidiary of Otsuka Pharmaceutical) under the brand name Eucapil. It is not approved by the United States Food and Drug Administration, the European Medicines Agency, or any other major regulatory authority for pharmaceutical use. The patent expired in 2020. This monograph reviews the chemistry, synthesis, rational design strategy, androgen receptor pharmacology, pharmacokinetics and serum lability, preclinical toxicology, the clinical evidence base, sourcing and handling considerations, comparator assessment against five alternative androgenetic alopecia agents, and the safety profile of topilutamide.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1519Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Cerebrolysin

Plain-language summaryIntrigue 65 / 100

Cerebrolysin is a porcine brain peptide hydrolysate used in Europe and Asia for stroke recovery and dementia. It contains a complex mixture of small peptides and amino acids. Available only as injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Eastern European-dominant neuropeptide mixture with real clinical footprint but unverifiable, consortium-dominated evidence

Look, Cerebrolysin occupies a genuinely strange corner of the research landscape. It’s a porcine brain-derived peptide mixture that’s been a registered pharmaceutical in Austria, Russia, China, and roughly 50 other countries since the 1970s, yet you won’t find it approved in the US, Canada, or most of Western Europe. That regulatory asymmetry tells you something.

The mechanism story is legitimately interesting, if frustratingly hard to pin down. The preparation contains low-molecular-weight peptides with sequences homologous to BDNF, NGF, GDNF, and CNTF, plus about 15 percent free amino acids. In theory, hitting all four major neurotrophic axes simultaneously should be powerful. The problem is that it’s a mixture, and that creates an attribution nightmare at the bench. You can observe effects, but isolating which fraction is doing what is genuinely difficult. The BBB penetration data looks real in animal models, but the pharmacokinetics of a biological mixture don’t behave like a small molecule, and nothing in the existing literature isolates a clean dose-response for any individual constituent.

The evidence base is where things get uncomfortable. There are dozens of trials, including multi-center work in ischemic stroke (the CASTA trial) and Alzheimer’s disease. But the preponderance of that literature comes from Austrian, Eastern European, Russian, and Chinese research groups, often without the methodological rigor that Western journals demand. The replication problem is real. Independent labs haven’t picked this up the way they’ve validated BPC-157’s basic wound-healing biology, for instance. Decades of literature and verified evidence aren’t the same thing.

Differentiation within the neurotrophic preparation space is worth noting. Cerebrolysin is almost certainly the most studied compound in this class; competitors like Cortexin and Actovegin have even thinner evidence bases. Semax and P21 offer cleaner mechanism stories because they’re defined single molecules, which makes them better bench tools even if they lack Cerebrolysin’s clinical footprint. That’s a real trade-off worth thinking about before committing a research program to this compound.

What we like: the translational signal is real enough. Patients have been receiving this compound clinically for decades across a huge geographic range. The stroke and TBI indications have plausible mechanistic underpinning and some meaningful clinical effect size in compliant trials. What we dont like: that evidence is genuinely hard to appraise from outside the originating institutions. For a bench scientist who needs to build on existing literature, that opacity is a serious practical obstacle.

Honestly, Cerebrolysin is worth knowing about, particularly if your research program touches neuroprotection or neurotrophic biology. But don’t expect to pull clean mechanistic conclusions from the existing literature. The signal is there, somewhere in that mixture. Verifying it cleanly is the open problem.

Novelty

32

Mechanism promise

52

In-category differentiation

42

Evidence quality

40

Translational signal

48

Research bench value

38

Rationale Cerebrolysin’s multi-neurotrophic mechanism hitting BDNF, NGF, GDNF, and CNTF homologs simultaneously is conceptually interesting, and its registered pharmaceutical status across 50-plus countries reflects a non-trivial translational signal; however, the evidence base is overwhelmingly sourced from Austrian, Eastern European, and Asian research groups with poor independent replication, making it difficult for bench scientists to build confidently on the existing foundation.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Porcine brain-derived neurotrophic peptide mixture with multimodal neuroprotective and neurorestorative activity

A standardized enzymatic hydrolysate of porcine brain tissue yielding low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic, neuroprotective, and neuroplasticity-promoting effects across stroke, traumatic brain injury, and neurodegenerative disease models.

Abstract

Cerebrolysin is a standardized, injectable preparation of enzymatically derived low-molecular-weight neuropeptides and free amino acids obtained from porcine brain tissue, manufactured by EVER Neuro Pharma (formerly EBEWE Pharma) in Unterach, Austria. The preparation contains peptide fragments exclusively below 10,000 Daltons in molecular weight, including sequences homologous to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), together with approximately 15 percent free amino acids by mass. First developed in 1949 by Gerhard Harrer at the University of Graz and subsequently refined through enzymatic hydrolysis standardization at EBEWE Pharma beginning in 1972, the compound has been registered as a pharmaceutical product in over 50 countries (excluding the United States, Canada, the United Kingdom, and most Western European Union member states) for indications including stroke recovery, traumatic brain injury, and dementia syndromes.

The pharmacological profile of Cerebrolysin is characterized by multimodal neurotrophic and neuroprotective activity. The constituent peptides activate tropomyosin receptor kinase (Trk) signaling pathways, particularly TrkA and TrkB, initiating downstream MAPK/ERK and PI3K/Akt cascades that regulate neuronal survival, differentiation, and synaptic plasticity. Additional characterized mechanisms include inhibition of calpain-mediated cytoskeletal degradation, suppression of excitotoxic glutamate signaling, reduction of free radical formation, attenuation of microglial activation, and promotion of neurogenesis in the subventricular zone and hippocampal dentate gyrus. The low molecular weight of the constituent peptides permits transit across the blood-brain barrier, a property that distinguishes Cerebrolysin from recombinant full-length neurotrophic factors that do not achieve meaningful central nervous system concentrations after peripheral administration.

The clinical evidence base encompasses more than 200 clinical studies involving over 10,000 patients across stroke, traumatic brain injury, Alzheimer’s disease, vascular dementia, and pediatric neurodevelopmental indications. The Cerebrolysin and Recovery After Stroke (CARS) randomized, placebo-controlled, double-blind multicenter trial demonstrated large superiority of Cerebrolysin (30 mL per day for 21 days) over placebo on the Action Research Arm Test at day 90 (Mann-Whitney estimator 0.71, 95 percent confidence interval 0.63 to 0.79, P less than 0.0001). The Cerebrolysin Acute Stroke Treatment in Asia (CASTA) trial in 1,070 patients did not demonstrate superiority on the primary endpoint (National Institutes of Health Stroke Scale at day 90), although post hoc analysis in severe stroke (NIHSS greater than 12) showed a trend favoring Cerebrolysin. In Alzheimer’s disease, a meta-analysis of randomized controlled trials demonstrated significant improvement in cognitive function (standardized mean difference negative 0.40 on the ADAS-cog at 4 weeks) and global clinical change compared to placebo, with safety comparable to placebo. In traumatic brain injury, 27 clinical studies enrolling 9,752 patients have demonstrated improvements in consciousness level, cognitive performance, and neurological outcomes.

The safety profile across controlled clinical trials is favorable, with adverse event rates comparable to placebo in most analyses. The principal adverse events are vertigo, agitation, feeling hot, headache, and dizziness. Rare anaphylactic reactions have been reported. The compound is contraindicated in epilepsy and severe renal impairment. This monograph reviews the composition, manufacturing, and quality standardization of Cerebrolysin; the multimodal neurotrophic and neuroprotective pharmacology; the pharmacokinetic profile including blood-brain barrier penetration; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five neurotrophic or neuroprotective alternatives (Cortexin, P21, NSI-189, Actovegin, Semax) against Cerebrolysin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1492Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026

←Previous Page

1 … 16 17 18 19 20 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.